3D InSight™ Mitochondrial Toxicity Testing Service | InSphero

Assess mitochondrial liabilities with advanced, organotypic 3D liver microtissues

3D InSight™ Mitochondrial Toxicity Testing uses a robust and highly predictive two-step assay to combine organotypic 3D liver microtissues with state of the art label-free mitochondrial function analysis on the Seahorse XFe96 Analyzer (Agilent Technologies). The longer in vitro lifespan of 3D InSight™ Human Liver Microtissues enables extended culture and flexible drug exposure times with repeat dosing.

  • Study long-term drug exposure effects with repeat dosing in a highly predictive two-step assay
  • Perform label-free assessment of oxygen consumption rate (OCR) by combining 3D InSight™ Human Liver Microtissues with the Seahorse XFe96 Analyzer
  • Identify mitochondrial liabilities with high sensitivity and specificity in a primary 3D liver model with higher spare respiratory capacity (SRC) than 2D monolayer hepatocyte cultures

Service Description

Service at a Glance

Download our brochure for details on the standard service protocol, which includes:

  • Phase I: Dose range-finding for cell viability
  • Phase II: OCR analysis on Seahorse XFe96 and cell viability
  • Analysis of compounds regarding mitochondrial liability based on viability and SRC dose response curves
  • Customization: Drug exposure times for Phase II can be customized (up to 14 days). The number and timing of repeat dosings will vary based on the length of drug exposure
Catalog # Description
SP-02-210-01 3D InSight™ Mitochondrial Toxicity Testing

Microtissues and Kits


Request Additional Resources

Brochure: Mitochondrial Toxicity Testing


Poster: Mitochondrial Activity Assessment


Webinar: Understanding Cellular Metabolism of Spheroids Using Extracellular Flux Technology

Find out how you can identify mitochondrial liabilities

with greater confidence.

Get Started